Regarding “IOM offers comparative-effectiveness priorities”
Now that we have $1.1 billion for comparative-effectiveness studies, it is time we investigated the cost and quality of life benefits of lifestyle changes. For example, what is a more effective and better use of resources: medications for diabetes, hypertension, coronary disease or improved diet, weight loss, exercise and stress management? Surgeons, pharmaceutical companies and medical-device makers should all be forced to include a group of lifestyle-change patients in their studies. We cannot afford to ignore this long-lost therapeutic avenue any longer.
Kevin Byrne, M.D., M.P.H.San Diego